Gbola Amusa
Stock Analyst at Chardan Capital
(1.98)
# 2,797
Out of 4,829 analysts
61
Total ratings
40%
Success rate
2.87%
Average return
Main Sectors:
Stocks Rated by Gbola Amusa
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADVM Adverum Biotechnologies | Downgrades: Neutral | $200 → $50 | $2.81 | +1,679.36% | 2 | Apr 29, 2021 | |
| TSHA Taysha Gene Therapies | Maintains: Buy | $60 → $68 | $2.13 | +3,069.01% | 3 | Apr 13, 2021 | |
| FBRX Forte Biosciences | Maintains: Buy | $2,875 → $2,625 | $6.29 | +41,632.91% | 4 | Mar 17, 2021 | |
| SLDB Solid Biosciences | Maintains: Buy | $188 → $300 | $2.76 | +10,769.57% | 5 | Mar 16, 2021 | |
| PASG Passage Bio | Maintains: Buy | $36 → $45 | $0.33 | +13,569.50% | 3 | Mar 8, 2021 | |
| MCRB Seres Therapeutics | Upgrades: Buy | $550 → $600 | $7.06 | +8,404.61% | 2 | Mar 5, 2021 | |
| QURE uniQure | Maintains: Buy | $85 → $100 | $12.79 | +681.86% | 4 | Mar 2, 2021 | |
| SYBX Synlogic | Maintains: Buy | $75 → $150 | $1.12 | +13,292.86% | 2 | Jan 13, 2021 | |
| IOVA Iovance Biotherapeutics | Maintains: Buy | $53 → $50 | $1.75 | +2,757.14% | 3 | Oct 6, 2020 | |
| IMVT Immunovant | Maintains: Buy | $35 → $45 | $14.02 | +220.97% | 3 | Aug 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $100 → $115 | $132.18 | -13.00% | 2 | Aug 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $73 → $100 | $35.62 | +180.74% | 1 | Jul 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $95 | $24.25 | +291.75% | 2 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $19 → $15 | $5.99 | +150.63% | 4 | Aug 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $130 | $7.52 | +1,628.72% | 4 | Jul 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $100 | $0.80 | +12,428.19% | 6 | Mar 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $2.5 → $2 | $684.59 | -99.71% | 2 | Jan 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $6.57 | - | 3 | Nov 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $300 → $350 | $527.78 | -33.68% | 6 | Dec 12, 2016 |
Adverum Biotechnologies
Apr 29, 2021
Downgrades: Neutral
Price Target: $200 → $50
Current: $2.81
Upside: +1,679.36%
Taysha Gene Therapies
Apr 13, 2021
Maintains: Buy
Price Target: $60 → $68
Current: $2.13
Upside: +3,069.01%
Forte Biosciences
Mar 17, 2021
Maintains: Buy
Price Target: $2,875 → $2,625
Current: $6.29
Upside: +41,632.91%
Solid Biosciences
Mar 16, 2021
Maintains: Buy
Price Target: $188 → $300
Current: $2.76
Upside: +10,769.57%
Passage Bio
Mar 8, 2021
Maintains: Buy
Price Target: $36 → $45
Current: $0.33
Upside: +13,569.50%
Seres Therapeutics
Mar 5, 2021
Upgrades: Buy
Price Target: $550 → $600
Current: $7.06
Upside: +8,404.61%
uniQure
Mar 2, 2021
Maintains: Buy
Price Target: $85 → $100
Current: $12.79
Upside: +681.86%
Synlogic
Jan 13, 2021
Maintains: Buy
Price Target: $75 → $150
Current: $1.12
Upside: +13,292.86%
Iovance Biotherapeutics
Oct 6, 2020
Maintains: Buy
Price Target: $53 → $50
Current: $1.75
Upside: +2,757.14%
Immunovant
Aug 25, 2020
Maintains: Buy
Price Target: $35 → $45
Current: $14.02
Upside: +220.97%
Aug 19, 2020
Maintains: Buy
Price Target: $100 → $115
Current: $132.18
Upside: -13.00%
Jul 28, 2020
Maintains: Buy
Price Target: $73 → $100
Current: $35.62
Upside: +180.74%
Jul 15, 2020
Maintains: Buy
Price Target: $84 → $95
Current: $24.25
Upside: +291.75%
Aug 17, 2018
Downgrades: Neutral
Price Target: $19 → $15
Current: $5.99
Upside: +150.63%
Jul 16, 2018
Maintains: Buy
Price Target: $90 → $130
Current: $7.52
Upside: +1,628.72%
Mar 27, 2018
Maintains: Neutral
Price Target: $75 → $100
Current: $0.80
Upside: +12,428.19%
Jan 10, 2018
Upgrades: Neutral
Price Target: $2.5 → $2
Current: $684.59
Upside: -99.71%
Nov 10, 2017
Upgrades: Buy
Price Target: n/a
Current: $6.57
Upside: -
Dec 12, 2016
Upgrades: Neutral
Price Target: $300 → $350
Current: $527.78
Upside: -33.68%